TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37262929

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saliva insulin
Number of subjects: 0
Study: 37262961

Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib (600 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib
Number of subjects: 0
Study: 37263066

Group type: COMPARATOR
Intervention: 120 %BW (20 % increased bodyweight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 10

Group type: COMPARATOR
Intervention: 120 %BW
Number of subjects: 10
Study: 37263121

Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: CTEPH incidence
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: 3-step triage algorithm
Number of subjects: 1191
Study: 37263361

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL) without resection combined with single-incision needle-knife (SINK) biopsy sampling
Number of subjects: 122
Study: 37263380

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059
Study: 37263523

Group type: EXPERIMENTAL
Intervention: Sapropterin (n = 43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 86
Study: 37263649

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL)
Number of subjects: 530
Study: 37263673

Group type: EXPERIMENTAL
Intervention: KN046 administered at doses of 1, 3, and 5 mg/kg every 2 weeks (Q2W), 5 mg/kg every 3 weeks (Q3W), and 300 mg Q3W.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KN046
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KN046 in NPC subgroup
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KN046 in EGFR-mutant NSCLC subgroup
Number of subjects: 100
Study: 37263683

Group type: EXPERIMENTAL
Intervention: High-dose oral antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 0
Study: 37263684

Group type: EXPERIMENTAL
Intervention: Community-based falls prevention programme with group-based strength and balance exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 60
Study: 37263708

Group type: EXPERIMENTAL
Intervention: Stepped-care programme (DWM and PM+)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Enhanced care as usual (eCAU)
Number of subjects: 232
Study: 37263896

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 37263914

Group type: EXPERIMENTAL
Intervention: Mixed nuts (42.5 g/day)
Number of subjects: 29
Study: 37263977

Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing
Number of subjects: 0
Study: 37264091

Group type: EXPERIMENTAL
Intervention: PhenoTIL (immune-related biomarker)
Number of subjects: 1774

Group type: EXPERIMENTAL
Intervention: PhenoTIL
Number of subjects: 1774
Study: 37264143

Group type: EXPERIMENTAL
Intervention: RenalGuard system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment (pre- and postprocedural intravenous hydration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study: 37264295

Group type: EXPERIMENTAL
Intervention: Orsiro Mission stent with 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resolute Onyx stent with 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study: 37264321

Group type: EXPERIMENTAL
Intervention: Radiotherapy ± chemotherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transoral Laser Microsurgery (TLM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Trans-Oral Robotic Surgery (TORS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study: 37264374

Group type: EXPERIMENTAL
Intervention: Deep learning diagnostic tool (DeepBreath) using convolutional neural networks, long short-term memory models, and transformer architectures.
Number of subjects: 120
Study: 37264399

Group type: EXPERIMENTAL
Intervention: Epidemiological Intelligence Community Network (EpI-Net) intervention workshops
Number of subjects: 24
Study: 37264471

Group type: EXPERIMENTAL
Intervention: Mobilised (ICU Mobility Scale (IMS) ≥ 3)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Not mobilised due to physiological reasons (IMS < 3)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Not mobilised due to non-physiological reasons (IMS < 3)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Mobilised (admitted for ≤ 3 days)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Not mobilised with physiological reasons (admitted for ≤ 3 days)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Not mobilised with non-physiological reasons (admitted for ≤ 3 days)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Low-risk patients (without non-physiological barriers)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Potential-risk patients (without non-physiological barriers)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Mobility association
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Low-risk patients mobilised
Number of subjects: 960
Study: 37264472

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 244
Study: 37264484

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg, subcutaneously)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline (0.2 ml, subcutaneously)
Number of subjects: 62
Study: 37264683

Group type: EXPERIMENTAL
Intervention: Early rhythm control
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: PRS-AF
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: PRS-stroke
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1567
Study: 37264699

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37264734

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37264767

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 251

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study: 37264909

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 2853

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2853
Study: 37264993

Group type: EXPERIMENTAL
Intervention: Adalimumab (subcutaneous administration at doses following the package insert)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 83
Study: 37265222

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Semaglutide treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of aerobic training and semaglutide treatment
Number of subjects: 31
Study: 37265259

Group type: EXPERIMENTAL
Intervention: Combination of lenacapavir plus teropavimab and zinlirvimab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LA injectable cabotegravir with bNAb VRC07-523LS
Number of subjects: 20
Study: 37265333

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -15 mmHg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -30 mmHg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -45 mmHg
Number of subjects: 30
Study: 37265355

Group type: EXPERIMENTAL
Intervention: Continuous finger-cuff arterial pressure monitoring
Number of subjects: 242

Group type: COMPARATOR
Intervention: Intermittent oscillometric arterial pressure monitoring
Number of subjects: 242
Study: 37265385

Group type: EXPERIMENTAL
Intervention: rhTNK-tPA (16 mg intravenous bolus)
Number of subjects: 767
Study: 37265412

Group type: EXPERIMENTAL
Intervention: Selpercatinib (Retevmo)
Number of subjects: 41
Study: 37265425

Group type: EXPERIMENTAL
Intervention: INBRX-109 (3 mg/kg every 3 weeks)
Number of subjects: 31
Study: 37265563

Group type: EXPERIMENTAL
Intervention: Predictive model based on six variables: New York Heart Association class, diabetes, glucose, blood urea nitrogen, operation time, and red blood cell transfusion during surgery.
Number of subjects: 7441

Group type: EXPERIMENTAL
Intervention: Predictive model
Number of subjects: 7441

Group type: COMPARATOR
Intervention: SinoSCORE
Number of subjects: 7441
Study: 37265566

Group type: EXPERIMENTAL
Intervention: AV-synchronous DDD pacing
Number of subjects: 40

Group type: COMPARATOR
Intervention: AV-asynchronous VVI pacing
Number of subjects: 40
Study: 37265662

Group type: EXPERIMENTAL
Intervention: Rare protein coding variants in tolerant patients (36)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (192)
Number of subjects: 228
Study: 37265710

Group type: EXPERIMENTAL
Intervention: Team Leaders
Number of subjects: 20

Group type: COMPARATOR
Intervention: CPR Coaches
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both Team Leaders and CPR Coaches
Number of subjects: 20
Study: 37265820

Group type: EXPERIMENTAL
Intervention: Long-term β-blocker therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: No β-blocker treatment
Number of subjects: 100
Study: 37265855

Group type: EXPERIMENTAL
Intervention: Remote cardiovascular risk service (CVRS) managed by clinical pharmacists for 12 months
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care for 12 months
Number of subjects: 401
Study: 37265868

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms applied to the SYNTAXES database with 75 pre-procedural variables.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms
Number of subjects: 0
Study: 37265937

Group type: EXPERIMENTAL
Intervention: ART-conceived children (IVF with fresh embryo transfer or frozen embryo transfer, NIFT)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: ART-conceived children
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Child group (ART-conceived)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Pregnancy group (ART-conceived)
Number of subjects: 4000
Study: 37266128

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate Diabetes Prevention Program (VLC-DPP)
Number of subjects: 18
Study: 37266144

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37266404

Group type: EXPERIMENTAL
Intervention: balanceHOME program (functional balance training)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Passive-control period
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional face-to-face physiotherapy program
Number of subjects: 112
Study: 37266586

Group type: COMPARATOR
Intervention: Carbohydrate supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Collagen protein supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Whey protein supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Home-based light resistance training with whey protein
Number of subjects: 66

Group type: COMPARATOR
Intervention: Center-based heavy-load resistance training with whey protein
Number of subjects: 66
Study: 37266823

Group type: EXPERIMENTAL
Intervention: Integrated PrEP and ART delivery
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ART/PrEP services adaptation during COVID-19 lockdown
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Multi-month refills, visits to clinics close to home, transport to clinics for providers, delivery of refills in neighborhoods
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Community delivery and pre-refill HIV testing requirements
Number of subjects: 78
Study: 37266939

Group type: EXPERIMENTAL
Intervention: Continuous bedside pressure mapping (CBPM) technology used by nursing staff for 72 hours
Number of subjects: 678

Group type: COMPARATOR
Intervention: Control group (no CBPM technology)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Continuous bedside pressure mapping (CBPM) technology
Number of subjects: 678
Study: 37266941

Group type: EXPERIMENTAL
Intervention: Sensory-adapted dental environment (SADE)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Regular dental environment (RDE)
Number of subjects: 162
Study: 37266942

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) with standard chemoradiation (cisplatin 100 mg/m2, RT 69.96 Gy) followed by adjuvant bevacizumab (15 mg/kg) with cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/d)
Number of subjects: 44
Study: 37266940

Group type: EXPERIMENTAL
Intervention: Targeted quality improvement intervention (n=5689)
Number of subjects: 12132

Group type: COMPARATOR
Intervention: Usual care (n=6443)
Number of subjects: 12132

Group type: EXPERIMENTAL
Intervention: Targeted quality improvement intervention in secondary hospitals
Number of subjects: 12132

Group type: EXPERIMENTAL
Intervention: Targeted quality improvement intervention for IV rtPA administration in secondary hospitals
Number of subjects: 12132

Group type: EXPERIMENTAL
Intervention: Targeted quality improvement intervention for EVT in secondary hospitals
Number of subjects: 12132
Study: 37266943

Group type: EXPERIMENTAL
Intervention: Bisensory treatment (combined auditory and somatosensory) for 30 minutes per day for 6 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Auditory-only treatment for 30 minutes per day for 6 weeks
Number of subjects: 99
Study: 37266947

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Low-Molecular-Weight Heparin (LMWH)
Number of subjects: 671
Study: 37266982

Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) with removable plates
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Extraction of both upper deciduous canines (DC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group with adequate upper arch space
Number of subjects: 76
Study: 37266993

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 1500
Study: 37267038

Group type: EXPERIMENTAL
Intervention: eSCCIP/eSCCIP-SP intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 350
Study: 37267169

Group type: EXPERIMENTAL
Intervention: COVID-19 impact on recovery
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Past-month opioid use
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI-II) score ≥10
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Managing substance use and treatment of OUD
Number of subjects: 216
Study: 37267179

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Noncontingent (NC) control group
Number of subjects: 158
Study: 37267394

Group type: EXPERIMENTAL
Intervention: 20 mg Melatonin orally daily for two consecutive menstrual cycles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo orally daily for two consecutive menstrual cycles
Number of subjects: 40
Study: 37267439

Group type: EXPERIMENTAL
Intervention: IDH mutations (IDHmut)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: IDH mutations with NPM1 mutation (IDHmut/NPM1mut)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: IDH mutations with DNMT3A or FLT3-ITD mutations
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: IDH mutations
Number of subjects: 3141
Study: 37267443

Group type: EXPERIMENTAL
Intervention: Galantamine plus risperidone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 37267720

Group type: EXPERIMENTAL
Intervention: Serum metabolome, adiponectin, inflammatory markers, and insulin-like growth factor-binding protein-1 phosphoisoforms analyzed at GDM diagnosis
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combination of IDL cholesterol, early gestational weight gain, fasting and 2-h glucose from oral glucose tolerance test
Number of subjects: 119
Study: 37267732

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Number of subjects: 400

Group type: COMPARATOR
Intervention: Lowest serum BDNF quartile
Number of subjects: 400

Group type: COMPARATOR
Intervention: Baseline non-depressed individuals
Number of subjects: 400
Study: 37267804

Group type: EXPERIMENTAL
Intervention: GM-CSF 125 μg/m
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 37267809

Group type: EXPERIMENTAL
Intervention: DiabeText (usual care + five text messages per week)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 207
Study: 37267853

Group type: EXPERIMENTAL
Intervention: MAMAACT intervention (six-hour training session for midwives, two follow-up dialog meetings, health education materials in six languages)
Number of subjects: 4150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4150
Study: 37268010

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: More intensive cryotherapy treatment
Number of subjects: 55
Study: 37268011

Group type: EXPERIMENTAL
Intervention: Aerobic training for 1 year
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (maintained lifestyle without additional exercise)
Number of subjects: 100
Study: 37268036

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation
Number of subjects: 379
Study: 37268157

Group type: EXPERIMENTAL
Intervention: Atezolizumab subcutaneous (SC) 1875 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Atezolizumab intravenous (IV) 1200 mg
Number of subjects: 371
Study: 37268222

Group type: EXPERIMENTAL
Intervention: DIALIVE liver dialysis device
Number of subjects: 32
Study: 37268435

Group type: EXPERIMENTAL
Intervention: Elamipretide 40 mg/d for 24 weeks
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 37268445

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anaesthetic-induced unresponsiveness
Number of subjects: 39

Group type: COMPARATOR
Intervention: NREM sleep
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anaesthesia
Number of subjects: 39
Study: 37268519

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX plus ramucirumab (Arm A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: mFOLFIRINOX plus placebo (Arm B)
Number of subjects: 82
Study: 37268553

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 15
Study: 37268628

Group type: EXPERIMENTAL
Intervention: Anodal tDCS during cognitive training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham tDCS during cognitive training
Number of subjects: 48
Study: 37268640

Group type: EXPERIMENTAL
Intervention: Parameters of arterial stiffness measured with the SphygmoCor System (AtCor Medical)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 266
Study: 37268656

Group type: EXPERIMENTAL
Intervention: Triheptanoin at maximum tolerable dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triheptanoin with ketogenic diet
Number of subjects: 10
Study: 37268724

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 57
Study: 37268772

Group type: EXPERIMENTAL
Intervention: Smartphone-based tapping task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Medication dose
Number of subjects: 32
Study: 37268802

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Face mask oxygen therapy
Number of subjects: 195
Study: 37268843

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus inferior alveolar nerve block (IANB)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB)
Number of subjects: 152
Study: 37268907

Group type: EXPERIMENTAL
Intervention: Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA) intervention
Number of subjects: 0
Study: 37268935

Group type: EXPERIMENTAL
Intervention: N-Tidal™ device for diagnosing COPD
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Machine learning model (XGBoost)
Number of subjects: 295
Study: 37268961

Group type: EXPERIMENTAL
Intervention: Dynamic Soft Tissue Mobilization (DSTM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching
Number of subjects: 48
Study: 37268971

Group type: EXPERIMENTAL
Intervention: Modified tinnitus relieving sound (MTRS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Unmodified music (UM)
Number of subjects: 68
Study: 37269077

Group type: EXPERIMENTAL
Intervention: Good effort on cognitive tests (defined as not exhibiting poor effort)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Poor effort on one cognitive test
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Poor effort on two cognitive tests
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Baseline cognitive testing effort
Number of subjects: 237
Study: 37269076

Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - single doses of 10-800 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - multiple doses of 25-100 mg once daily or 500 mg once weekly
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - bioavailability as a tablet versus powder-in-bottle
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 37269192

Group type: EXPERIMENTAL
Intervention: Exercise intervention (176.4±63.5 min/week)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 144
Study: 37269282

Group type: EXPERIMENTAL
Intervention: Cervical and thoracic transcutaneous spinal cord stimulation (scTS)
Number of subjects: 7
Study: 37269344

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828) at a maximum tolerated dose of 60 mg for D1q3w and 45 mg for D1D8q4w
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 54